Cargando…
Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis
BACKGROUND: Pioglitazone was used to treat patients of PCOS in many researches, but the treatment has not been recognized by public or recommended by all the guidelines. METHOD: We conducted a meta-analysis of the related literatures to objectively evaluate the clinical effectiveness and safety by c...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591817/ https://www.ncbi.nlm.nih.gov/pubmed/28770353 http://dx.doi.org/10.1007/s00404-017-4480-z |
_version_ | 1783262785776386048 |
---|---|
author | Xu, Yifeng Wu, Yanxiang Huang, Qin |
author_facet | Xu, Yifeng Wu, Yanxiang Huang, Qin |
author_sort | Xu, Yifeng |
collection | PubMed |
description | BACKGROUND: Pioglitazone was used to treat patients of PCOS in many researches, but the treatment has not been recognized by public or recommended by all the guidelines. METHOD: We conducted a meta-analysis of the related literatures to objectively evaluate the clinical effectiveness and safety by comparing pioglitazone with metformin administrated by PCOS patients. Searches were performed in Cochrane Library, EMBASE and PubMed (last updated December 2016). RESULTS: Eleven studies among 486 related articles were identified through searches. Fixed effects and random effects models were used to calculate the overall risk estimates. The results of the meta-analysis suggest that improvement of the menstrual cycle and ovulation in pioglitazone treatment group was better than metformin group [OR = 2.31, 95% CI (1.37, 3.91), P < 0.001, I (2) = 41.8%]. Improvement of the F-G scores in metformin treatment group was better than pioglitazone group [SMD = 0.29, 95% CI (0.0, 0.59), P = 0.048, I (2) = 0.0%]. BMI was more elevated in pioglitazone group than in metformin group [SMD = 0.83, 95% CI (0.24, 1.41), P = 0.006, I (2) = 82.8%]. There were no significant differences of the other data between the two groups. CONCLUSIONS: This meta-analysis indicated that pioglitazone ameliorated menstrual cycle and ovulation better than metformin and metformin ameliorated BMI and F-G scores better than pioglitazone in treating patients with PCOS. Pioglitazone might be a good choice for the patients with PCOS who were intolerant or invalid to metformin for the treatment. |
format | Online Article Text |
id | pubmed-5591817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-55918172017-09-25 Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis Xu, Yifeng Wu, Yanxiang Huang, Qin Arch Gynecol Obstet Review BACKGROUND: Pioglitazone was used to treat patients of PCOS in many researches, but the treatment has not been recognized by public or recommended by all the guidelines. METHOD: We conducted a meta-analysis of the related literatures to objectively evaluate the clinical effectiveness and safety by comparing pioglitazone with metformin administrated by PCOS patients. Searches were performed in Cochrane Library, EMBASE and PubMed (last updated December 2016). RESULTS: Eleven studies among 486 related articles were identified through searches. Fixed effects and random effects models were used to calculate the overall risk estimates. The results of the meta-analysis suggest that improvement of the menstrual cycle and ovulation in pioglitazone treatment group was better than metformin group [OR = 2.31, 95% CI (1.37, 3.91), P < 0.001, I (2) = 41.8%]. Improvement of the F-G scores in metformin treatment group was better than pioglitazone group [SMD = 0.29, 95% CI (0.0, 0.59), P = 0.048, I (2) = 0.0%]. BMI was more elevated in pioglitazone group than in metformin group [SMD = 0.83, 95% CI (0.24, 1.41), P = 0.006, I (2) = 82.8%]. There were no significant differences of the other data between the two groups. CONCLUSIONS: This meta-analysis indicated that pioglitazone ameliorated menstrual cycle and ovulation better than metformin and metformin ameliorated BMI and F-G scores better than pioglitazone in treating patients with PCOS. Pioglitazone might be a good choice for the patients with PCOS who were intolerant or invalid to metformin for the treatment. Springer Berlin Heidelberg 2017-08-02 2017 /pmc/articles/PMC5591817/ /pubmed/28770353 http://dx.doi.org/10.1007/s00404-017-4480-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Xu, Yifeng Wu, Yanxiang Huang, Qin Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis |
title | Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis |
title_full | Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis |
title_fullStr | Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis |
title_full_unstemmed | Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis |
title_short | Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis |
title_sort | comparison of the effect between pioglitazone and metformin in treating patients with pcos:a meta-analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591817/ https://www.ncbi.nlm.nih.gov/pubmed/28770353 http://dx.doi.org/10.1007/s00404-017-4480-z |
work_keys_str_mv | AT xuyifeng comparisonoftheeffectbetweenpioglitazoneandmetforminintreatingpatientswithpcosametaanalysis AT wuyanxiang comparisonoftheeffectbetweenpioglitazoneandmetforminintreatingpatientswithpcosametaanalysis AT huangqin comparisonoftheeffectbetweenpioglitazoneandmetforminintreatingpatientswithpcosametaanalysis |